A novel exvivo murine retina angiogenesis (EMRA) assay

Experimental Eye Research

Volumn 112, Issue , 2013, Pages 51-56

  Rezzola, Sara ^a   Belleri, Mirella ^a   Ribatti, Domenico ^b   Costagliola, Ciro ^c   Presta, Marco ^a   Semeraro, Francesco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Endothelium; Mouse; Ranibizumab; Retina; VEGF

Indexed keywords

BEVACIZUMAB; FIBRINOGEN; RANIBIZUMAB; RECOMBINANT VASCULOTROPIN; ANGIOGENESIS INHIBITOR; FIBRIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTA; ASSAY; EX VIVO MURINE RETINA ANGIOGENESIS ASSAY; IN VITRO STUDY; MICROENVIRONMENT; MICROSCOPE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA; RETINA NEOVASCULARIZATION; SHORT SURVEY; VASCULAR ENDOTHELIUM; ANIMAL; ARTICLE; BIOASSAY; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METHODOLOGY; ORGAN CULTURE TECHNIQUE; PATHOLOGY; RETINA BLOOD VESSEL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBRIN; MICE; MICE, INBRED C57BL; ORGAN CULTURE TECHNIQUES; RECOMBINANT PROTEINS; RETINA; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877903712     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.04.014     Document Type: Short Survey

References (28)

1. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N.Engl. J. Med. 1994, 331:1480-1487.
2. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. N.Engl. J. Med. 2012, 366:1227-1239.
3. Bastaki M., Nelli E.E., Dell'Era P., Rusnati M., Molinari-Tosatti M.P., Parolini S., Auerbach R., Ruco L.P., Possati L., Presta M. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler. Thromb. Vasc. Biol. 1997, 17:454-464.
4. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
5. Chen J., Stahl A., Hellstrom A., Smith L.E. Current update on retinopathy of prematurity: screening and treatment. Curr. Opin. Pediatr. 2011, 23:173-178.
6. Chi J.T., Chang H.Y., Haraldsen G., Jahnsen F.L., Troyanskaya O.G., Chang D.S., Wang Z., Rockson S.G., van de Rijn M., Botstein D., Brown P.O. Endothelial cell diversity revealed by global expression profiling. Proc. Natl. Acad. Sci. 2003, 100:10623-10628.
7. Congdon N., O'Colmain B., Klaver C.C., Klein R., Munoz B., Friedman D.S., Kempen J., Taylor H.R., Mitchell P. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004, 122:477-485.
8. Costagliola C., Agnifili L., Arcidiacono B., Duse S., Fasanella V., Mastropasqua R., Verolino M., Semeraro F. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin. Biol. Ther. 2012, 12:1299-1313.
9. Friedman D.S., O'Colmain B.J., Munoz B., Tomany S.C., McCarty C., de Jong P.T., Nemesure B., Mitchell P., Kempen J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122:564-572.
10. Gariano R.F., Gardner T.W. Retinal angiogenesis in development and disease. Nature 2005, 438:960-966.
11. Goodwin A.M. Invitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc. Res. 2007, 74:172-183.
12. Kim L.A., D'Amore P.A. Abrief history of anti-VEGF for the treatment of ocular angiogenesis. Am. J. Pathol. 2012, 181:376-379.
13. Klein B.E. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007, 14:179-183.
14. Klettner A., Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib invitro: efficiency and possible additional pathways. Invest. Ophthalmol. Vis. Sci. 2008, 49:4523-4527.
15. Mechoulam H., Pierce E.A. Retinopathy of prematurity: molecular pathology and therapeutic strategies. Am. J. Pharmacogenomic. 2003, 3:261-277.
16. Miller J.W., Le Couter J., Strauss E.C., Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013, 120:106-114.
17. Montezuma S.R., Vavvas D., Miller J.W. Review of the ocular angiogenesis animal models. Semin. Ophthalmol. 2009, 24:52-61.
18. Murakami T., Suzuma K., Takagi H., Kita M., Ohashi H., Watanabe D., Ojima T., Kurimoto M., Kimura T., Sakamoto A., Unoki N., Yoshimura N. Time-lapse imaging of vitreoretinal angiogenesis originating from both quiescent and mature vessels in a novel exvivo system. Invest. Ophthalmol. Vis. Sci. 2006, 47:5529-5536.
19. Nicosia R.F. The aortic ring model of angiogenesis: a quarter century of search and discovery. J.Cell. Mol. Med. 2009, 10:4113-4136.
20. Sawamiphak S., Ritter M., Acker-Palmer A. Preparation of retinal explant cultures to study exvivo tip endothelial cell responses. Nat. Protoc. 2010, 5:1659-1665.
21. Semeraro F., Parrinello G., Cancarini A., Pasquini L., Zarra E., Cimino A., Cancarini G., Valentini U., Costagliola C. Predicting the risk of diabetic retinopathy in type 2 diabetic patients. J.Diabet. Complications 2011, 25:292-297.
22. Siemerink M.J., Augustin A.J., Schlingemann R.O. Mechanisms of ocular angiogenesis and its molecular mediators. Dev. Ophthalmol. 2010, 46:4-20.
23. Stahl A., Connor K.M., Sapieha P., Chen J., Dennison R.J., Krah N.M., Seaward M.R., Willett K.L., Aderman C.M., Guerin K.I., Hua J., Lofqvist C., Hellstrom A., Smith L.E. The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 2010, 51:2813-2826.
24. Staton C.A., Reed M.W. Acritical analysis of current invitro and invivo angiogenesis assays. Int. J. Exp. Pathol. 2009, 90:195-221.
25. Stewart E.A., Samaranayake G.J., Browning A.C., Hopkinson A., Amoaku W.M. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments. Exp. Eye Res. 2011, 93:761-766.
26. Stewart M.W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc. 2012, 87:77-88.
27. Su X., Sorenson C.M., Sheibani N. Isolation and characterization of murine retinal endothelial cells. Mol. Vis. 2003, 9:171-178.
28. Zetter B.R. Endothelial heterogeneity: influence of vessel size, organ localization, and species specificity on the properties of cultured endothelial cells. Endothelial Cells 1988, vol. 2:64-79. CRC Press, Boca Raton, USA.